Companion Animal Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Animal Type (Dogs, Cats, Horses, Others), By Technology (Clinical Biochemistry, Clinical Chemistry Analysis, Glucose Monitoring, Blood Gas & Electrolyte Analysis, Immunodiagnostics, Hematology, Urinalysis, Others), By Region and Competition, 2020-2030F

Market Overview

Global Companion Animal Diagnostics Market was valued at USD 2.80 Billion in 2024 and is expected to reach USD 4.20 Billion by 2030 with a CAGR of 7.21%. As more households treat their pets as family members, there is a growing emphasis on regular health check-ups and early disease detection, which in turn is driving the demand for advanced diagnostic tools and services. This shift in consumer behavior has elevated the role of diagnostics in ensuring the well-being of companion animals such as dogs, cats, and other household pets.

A key factor contributing to market expansion is the continuous innovation in diagnostic technologies. Modern diagnostic platforms now offer faster, more accurate, and non-invasive testing methods. The development of point-of-care testing kits, molecular diagnostics, and advanced imaging techniques has significantly improved the ability of veterinarians to diagnose a wide range of conditions, from infectious diseases to chronic illnesses and genetic disorders. Despite the optimistic outlook, the market does face challenges, particularly related to the high cost of advanced diagnostic equipment and the limited availability of skilled veterinary professionals in some regions.

Key Market Drivers

Growth in Healthcare Industry

The steady growth of the global healthcare industry has had a significant influence on the expansion of the companion animal diagnostics market. The global healthcare industry generates annual revenues exceeding USD 4 trillion. Among its most significant and profitable segments are pharmaceuticals and biotechnology, which collectively account for nearly USD 850 billion, followed by medical technology and diagnostics, contributing over USD 400 billion. As healthcare systems continue to modernize and evolve, there has been a notable rise in investments and technological advancements within the veterinary segment, mirroring the progress seen in human healthcare. This parallel development has contributed to an increasing demand for accurate, efficient, and accessible diagnostic solutions for companion animals.

One of the major factors driving this growth is the rising humanization of pets, which has led to a greater focus on preventative healthcare and early disease detection. Pet owners, especially in developed economies, are increasingly willing to spend more on medical care for their animals, including routine diagnostic testing and advanced screening methods. The World Organisation for Animal Health (WOAH), formerly known as the Office International des Epizooties (OIE), is an intergovernmental body responsible for coordinating, supporting, and advancing efforts in animal disease control. Its core mandate is to manage epizootic diseases and prevent their transmission across regions. This growing awareness and willingness to invest in animal health has spurred the adoption of diagnostic technologies that were once limited to human healthcare, such as molecular diagnostics, imaging systems, and point-of-care testing.

Surge in Technological Advancements

The global companion animal diagnostics market is experiencing significant growth, largely propelled by rapid technological advancements that are transforming veterinary care. These innovations have enhanced diagnostic precision, accelerated turnaround times, and expanded the accessibility of diagnostic services for companion animals, thereby strengthening the market’s upward trajectory. directEsense is an advanced diagnostic technology that leverages expertise in electrochemical sensor engineering to eliminate detection labels and simplify device design, unlocking broader application potential. It uses an electrically active chemical layer on the sensor surface to enable direct detection of target analytes.

One of the most notable developments driving this growth is the advancement of point-of-care diagnostic tools. Portable and in-clinic testing devices now allow veterinarians to conduct real-time assessments of various health parameters, reducing the reliance on external laboratories. These tools deliver quick and reliable results, enabling timely intervention and improving clinical outcomes. Their ease of use and integration into routine veterinary practice have made them indispensable in small and mid-sized veterinary clinics.

Download Free Sample Report

Key Market Challenges

High Cost of Advanced Diagnostics

The high cost of advanced diagnostics remains a significant challenge in the global companion animal diagnostics market. While technological innovations have led to the development of highly accurate and efficient diagnostic tools, the financial burden associated with these technologies can hinder widespread adoption, particularly in cost-sensitive markets. Advanced diagnostic modalities such as molecular assays, genetic testing, and digital imaging systems often require substantial investment in equipment, infrastructure, and skilled personnel, which limits their accessibility to high-end veterinary clinics and specialty hospitals.

For many pet owners, particularly in developing regions, the cost of sophisticated diagnostic procedures may be prohibitively expensive. Unlike human healthcare, which is often subsidized or covered by public health systems, veterinary care is largely out-of-pocket. Even with the growing adoption of pet insurance, coverage is not always comprehensive, and reimbursement for advanced diagnostics may be limited. This creates disparities in the level of care available, as some pet owners may opt for basic diagnostic tests or forgo testing altogether due to financial constraints.

Key Market Trends

Growth of Specialized Diagnostic Modalities

The global companion animal diagnostics market is witnessing a marked shift toward specialized diagnostic modalities, which is emerging as a key trend driving market growth and innovation. As veterinary medicine continues to advance, there is an increasing emphasis on precision and early diagnosis, prompting the adoption of more sophisticated and targeted diagnostic tools tailored specifically for companion animals. For example, Pawsperity Biotechnologies is advancing companion animal healthcare through the development of innovative molecular diagnostic solutions that support precision veterinary medicine.

Specialized modalities such as molecular diagnostics, immunodiagnostics, and advanced imaging techniques have gained considerable traction in recent years. These technologies enable more accurate and rapid detection of diseases at the cellular and molecular level, often before clinical symptoms become evident. Molecular assays, for instance, are increasingly being used to detect genetic disorders, identify infectious agents, and monitor treatment responses in pets, offering veterinarians greater insight into disease progression and therapeutic efficacy.

Segmental Insights

Animal Type Insights

Based on Animal Type, Dogs have emerged as the fastest growing segment in the Global Companion Animal Diagnostics Market in 2024. One of the key factors contributing to this growth is the growing prevalence of chronic and infectious diseases among dogs, including conditions such as diabetes, arthritis, cancer, and tick-borne illnesses. The need for early detection and effective management of these diseases has accelerated the adoption of diagnostic tests ranging from hematology and biochemistry panels to molecular and imaging diagnostics. This heightened medical awareness is driving demand for frequent and sophisticated diagnostic evaluations, thereby expanding the market for canine-specific diagnostic products.

Technology Insights

Based on Technology, Clinical Biochemistry have emerged as the fastest growing segment in the Global Companion Animal Diagnostics Market during the forecast period. This is due to its critical role in the early detection, diagnosis, and monitoring of a wide range of diseases in pets. This segment provides essential insights into organ function, metabolic status, and overall health through the analysis of blood and other bodily fluids. With the increasing prevalence of chronic conditions such as diabetes, kidney disorders, and liver diseases in companion animals, veterinary professionals are placing greater emphasis on biochemistry panels as a routine diagnostic tool.

Download Free Sample Report

Regional Insights

Based on Region, North America have emerged as the dominating region in the Global Companion Animal Diagnostics Market in 2024. One of the key factors underpinning this dominance is the region’s strong culture of pet humanization, where companion animals are increasingly regarded as family members. This has led to a surge in demand for preventative healthcare, regular veterinary check-ups, and specialized diagnostics for conditions such as cancer, diabetes, and kidney disease. The willingness of pet owners in the U.S. and Canada to invest in high-quality veterinary care directly supports the expansion of diagnostic services.

Recent Development

• In March 2025, Antech, a globally recognized leader in veterinary diagnostics, technology, and imaging solutions, announced the commercial launch of trūRapid FOUR, a next-generation in-house diagnostic test designed for comprehensive screening of canine vector-borne diseases (CVBDs). This innovative lateral flow assay offers veterinarians a convenient and reliable method for the simultaneous detection of multiple pathogens. Specifically, trūRapid FOUR is engineered to identify canine antibodies to Anaplasma spp., Ehrlichia spp., and Lyme C6 (Borrelia burgdorferi), as well as antigen from heartworm (Dirofilaria immitis), using whole blood, serum, or plasma samples. By enabling rapid and accurate point-of-care diagnostics, the test is set to enhance early disease detection and improve treatment outcomes in clinical veterinary practice.
• In July 2024, BD (Becton, Dickinson and Company), a global leader in medical technology, and Quest Diagnostics, a prominent provider of diagnostic information services, announced a strategic global collaboration to develop, manufacture, and commercialize flow cytometry-based companion diagnostics (CDx). This initiative aims to support the identification of optimal treatment options for patients with cancer and other diseases. Through this partnership, BD and Quest seek to offer the pharmaceutical industry a comprehensive, end-to-end solution for CDx development spanning from exploratory panel design to the production and distribution of FDA-approved diagnostic kits.
• In March 2025, Zoetis Inc., in collaboration with the Federation of European Companion Animal Veterinary Associations (FECAVA) and the Federation of Veterinarians of Europe (FVE), launched The Human-Animal Bond Handbook: Best Practices to Advance Global Initiatives and Policies that Benefit Human and Animal Health during the second Companion Animal Stakeholder Summit in Brussels. This handbook offers practical case studies designed to support policymakers in developing frameworks that strengthen the human-animal bond, while also raising awareness among stakeholders and private-sector entities about initiatives that enhance the well-being of both people and their companion animals.
• In December 2024, IDEXX Laboratories, a global leader in veterinary healthcare, announced a series of strategic developments underscoring its dedication to innovation and operational excellence. These updates include leadership transitions and the introduction of advanced diagnostic technologies aimed at improving the health and well-being of pets, people, and livestock. Among the notable product launches is the IDEXX inVue Dx Cellular Analyzer an innovative, slide-free device that delivers reference-laboratory quality results within 10 minutes. Leveraging AI models developed by IDEXX pathologists, the analyzer offers multidimensional diagnostic insights for both ear and blood samples.

Key Market Players

• IDEXX Laboratories, Inc.
• Zoetis Inc.
• Virbac
• Heska Corporation
• Neogen Corporation
• Bio-Rad Laboratories, Inc.
• INDICAL Bioscience GmbH
• Agrolabo SpA
• ID.vet
• bioMérieux S.A.

Report Scope

In this report, the Global Companion Animal Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Companion Animal Diagnostics Market, By Animal Type:

o   Dogs

o   Cats

o   Horses

o   Others

• Companion Animal Diagnostics Market, By Technology:

o   Clinical Biochemistry

o   Clinical Chemistry Analysis

o   Glucose Monitoring

o   Blood Gas & Electrolyte Analysis

o   Immunodiagnostics

o   Hematology

o   Urinalysis

o   Others

• Companion Animal Diagnostics Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Companion Animal Diagnostics Market.

Available Customizations:

Global Companion Animal Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Companion Animal Diagnostics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]